Profile data is unavailable for this security.
About the company
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
- Revenue in USD (TTM)89.25m
- Net income in USD-172.40m
- Incorporated2012
- Employees173.00
- LocationProthena Corporation PLC77 Sir John Rogersons QuayBlock C, Grand Canal DocklandsDUBLIN D02 T804IrelandIRL
- Phone+353 12362500
- Fax+353 19023510
- Websitehttps://www.prothena.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.03bn | 267.00 | -- | -- | -- | 2.49 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.17 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Pharvaris NV | 0.00 | -114.99m | 1.07bn | 82.00 | -- | 2.77 | -- | -- | -2.57 | -2.57 | 0.00 | 7.22 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.08bn | 46.00 | -- | 3.37 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Silence Therapeutics plc | 33.58m | -44.43m | 1.08bn | 115.00 | -- | 6.20 | -- | 32.27 | -0.3904 | -0.3904 | 0.2851 | 1.13 | 0.1829 | -- | 5.37 | 291,970.60 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.12bn | 197.00 | 16.60 | 5.03 | 4.67 | 1.97 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.14bn | 586.00 | -- | 1.00 | -- | 31.72 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.15bn | 296.00 | -- | 5.09 | -- | 10.79 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 1.16bn | 593.00 | -- | 20.42 | -- | 8.23 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.16bn | 173.00 | -- | 2.31 | -- | 13.01 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.24bn | 278.00 | -- | 5.26 | -- | 5.52 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.28bn | 174.00 | -- | 4.30 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.29bn | 642.00 | 38.68 | 2.86 | 13.79 | 2.50 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
Data as of May 23 2024. Currency figures normalised to Prothena Corporation PLC's reporting currency: US Dollar USD
72.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Mar 2024 | 11.58m | 21.56% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 8.01m | 14.90% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.13m | 7.69% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 3.75m | 6.99% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.47m | 6.47% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.18m | 5.91% |
| Palo Alto Investors LPas of 31 Mar 2024 | 1.66m | 3.10% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.29m | 2.40% |
| Armistice Capital LLCas of 31 Mar 2024 | 1.10m | 2.04% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.01m | 1.87% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
